by Jordana Choucair | Jul 28, 2022 | Opioid/Substance Use Disorders
Allergan, a subsidiary of AbbVie, agreed to a $2 billion settlement with state and local governments to end thousands of lawsuits related to the marketing of its opioid Kadian. A federal court in Cleveland is working out details, such as the payout period and what...
by Jordana Choucair | Jul 27, 2022 | Opioid/Substance Use Disorders
Teva Pharmaceuticals reached a tentative $4.25 billion settlement with states and localities over its role in the opioid addiction crisis. The deal requires Teva to make payments to approximately 2,500 local governments, states, and tribes over the course of 13 years....
by Jordana Choucair | Jul 20, 2022 | Opioid/Substance Use Disorders
The Centers for Disease Control and Prevention (CDC) released new data indicating that overdose death rates surged among Black, American Indian, and Alaska Native individuals in 2020. According to the data from 25 states and the District of Columbia, the overdose...
by Jordana Choucair | Jul 14, 2022 | Opioid/Substance Use Disorders
A new study of fatal overdoses found that relaxing access to methadone did not lead to more deaths. In March 2020, the federal government told methadone clinics they could allow stable patients with opioid addiction to take their medicine at home unsupervised....
by Jordana Choucair | Jul 13, 2022 | Opioid/Substance Use Disorders
Teva Pharmaceutical Industries Ltd. and AbbVie Inc.’s Allergan unit will pay $34 million in cash and $20 million worth of overdose reversal drug Narcan to settle a federal lawsuit brought by San Francisco alleging that the drugmakers fueled the opioid surge,...
by Jordana Choucair | Jul 5, 2022 | Opioid/Substance Use Disorders
A federal judge on Monday ruled in favor of three major U.S. drug distributors in a landmark lawsuit that accused them of fueling the opioid crisis in Cabell County, West Virginia. The county and the city of Huntington argued that AmerisourceBergen Drug Co., Cardinal...
Recent Comments